Maria G. GuzmanScott B. HalsteadHarvey ArtsobPhilippe BuchyJeremy FarrarDuane J. GublerElizabeth HunspergerAxel KroegerHarold S. MargolisEric Martí-nezMichael B. NathanJose Luis PelegrinoCameron SimmonsSutee YoksanRosanna W. PeelingInstituto de Medicina Tropical Pedro KouriPediatric Dengue Vaccine InitiativeNational Microbiology LaboratoryInstitut Pasteur du CambodgeUCLDuke-NUS Graduate Medical School SingaporeCenters for Disease Control and Prevention San JuanOrganisation Mondiale de la SanteMahidol UniversityLondon School of Hygiene & Tropical Medicine2018-09-242018-09-242010-01-01Nature Reviews Microbiology. Vol.8, No.12 (2010), S7-S1617401534174015262-s2.0-79955602230https://repository.li.mahidol.ac.th/handle/123456789/29292Dengue fever and dengue haemorrhagic fever are important arthropod-borne viral diseases. Each year, there are ~50 million dengue infections and ~500,000 individuals are hospitalized with dengue haemorrhagic fever, mainly in Southeast Asia, the Pacific and the Americas. Illness is produced by any of the four dengue virus serotypes. A global strategy aimed at increasing the capacity for surveillance and outbreak response, changing behaviours and reducing the disease burden using integrated vector management in conjunction with early and accurate diagnosis has been advocated. Antiviral drugs and vaccines that are currently under development could also make an important contribution to dengue control in the future. © 2010 Macmillan Publishers Limited. All rights reserved.Mahidol UniversityImmunology and MicrobiologyArticleSCOPUS10.1038/nrmicro2460